Logo do repositório
 
Publicação

Exploring new pathways in endocrine-resistant breast cancer

2022Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorSoares De Pinho, Inês
dc.contributor.authorMarques, Catarina
dc.contributor.authorFernandes Gomes, Inês
dc.contributor.authorCasimiro, Sandra
dc.contributor.authorPacheco, Teresa
dc.contributor.authorSousa, Rita Teixeira de
dc.contributor.authorCosta, Luis
dc.date.accessioned2022-09-23T13:18:10Z
dc.date.available2022-09-23T13:18:10Z
dc.date.issued2022
dc.descriptionCopyright: © The Author(s) 2022. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.pt_PT
dc.description.abstractThe most common breast cancer (BC) subtypes are hormone-dependent, being either estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), or both, and altogether comprise the luminal subtype. The mainstay of treatment for luminal BC is endocrine therapy (ET), which includes several agents that act either directly targeting ER action or suppressing estrogen production. Over the years, ET has proven efficacy in reducing mortality and improving clinical outcomes in metastatic and nonmetastatic BC. However, the development of ET resistance promotes cancer survival and progression and hinders the use of endocrine agents. Several mechanisms implicated in endocrine resistance have now been extensively studied. Based on the current clinical and pre-clinical data, the present article briefly reviews the well-established pathways of ET resistance and continues by focusing on the three most recently uncovered pathways, which may mediate resistance to ET, namely receptor activator of nuclear factor kappa B ligand (RANKL)/receptor activator of nuclear factor kappa B (RANK), nuclear factor kappa B (NFκB), and Notch. It additionally overviews the evidence underlying the approval of combined therapies to overcome ET resistance in BC, while highlighting the relevance of future studies focusing on putative mediators of ET resistance to uncover new therapeutic options for the disease.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationExplor Target Antitumor Ther. 2022;3(3):337-361pt_PT
dc.identifier.doi10.37349/etat.2022.00086pt_PT
dc.identifier.eissn2692-3114
dc.identifier.urihttp://hdl.handle.net/10451/54564
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherOpen Exploration Publishing Inc.pt_PT
dc.relation.publisherversionhttps://www.explorationpub.com/Journals/etatpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectBreast cancerpt_PT
dc.subjectNotchpt_PT
dc.subjectEndocrine therapypt_PT
dc.subjectNuclear factor kappa Bpt_PT
dc.subjectReceptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa Bpt_PT
dc.subjectResistance mechanismspt_PT
dc.titleExploring new pathways in endocrine-resistant breast cancerpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage361pt_PT
oaire.citation.startPage337pt_PT
oaire.citation.titleExploration of Targeted Anti-tumor Therapypt_PT
person.familyNameSoares de Pinho
person.familyNameMarques
person.familyNameFernandes Gomes
person.familyNameCara de Anjo Casimiro
person.familyNamePacheco
person.familyNameTeixeira de Sousa
person.familyNameCosta
person.givenNameInês
person.givenNameCatarina
person.givenNameInês
person.givenNameSandra Cristina
person.givenNameTeresa
person.givenNameRita
person.givenNameLuis
person.identifier.ciencia-idB311-6AE6-9A83
person.identifier.ciencia-id4114-34EA-AD95
person.identifier.ciencia-id0F12-5181-0B22
person.identifier.ciencia-idA81D-84E4-6399
person.identifier.ciencia-id041E-4ADE-FB64
person.identifier.orcid0000-0002-8377-0179
person.identifier.orcid0000-0003-3558-3966
person.identifier.orcid0000-0003-0985-0821
person.identifier.orcid0000-0002-6917-4477
person.identifier.orcid0000-0002-5506-0233
person.identifier.orcid0000-0002-9147-7896
person.identifier.orcid0000-0002-4782-7318
person.identifier.scopus-author-id14043403400
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication175aa033-b64e-4a94-b8c8-8bed65034181
relation.isAuthorOfPublication02a5a89e-8c42-48b2-a57d-3dc22e046324
relation.isAuthorOfPublication730a372f-c20e-4327-a9a1-f84ea7dff0bb
relation.isAuthorOfPublicationfd665de1-a7e6-4638-94c3-ecc645f84607
relation.isAuthorOfPublication45c53fd3-4da2-4d58-8c15-b13968b8689d
relation.isAuthorOfPublicationa49dddc2-aab9-467c-b47f-485a1cde5883
relation.isAuthorOfPublication8a2ab4c6-ba86-4433-b4b7-6256d81890e5
relation.isAuthorOfPublication.latestForDiscoverya49dddc2-aab9-467c-b47f-485a1cde5883

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Exploring_pathways.pdf
Tamanho:
3.72 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

IMM - Artigos em Revistas Internacionais
FM - Artigos em Revistas Internacionais